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Abstract
Background: The optimal conduct of follow-up (FU) of patients with osteosarcoma is uncertain. In the absence of
any formal validation of optimal timing and method of surveillance, guidance is provided by oncology societies’
recommendations. FU is designed to detect either local recurrence or metastatic disease at a time when early
treatment is still possible and might be effective.
Methods: We performed a retrospective analysis of 101 patients with high-grade extremity osteosarcoma in a
single centre. Chest x-ray (CXR) was used as routine surveillance method; however patients with initial lung
metastases or previous suspicious findings had computed tomography (CT) scans.
Results: With a median FU time of 30.7 months 34 patients relapsed. Relapse–free survival after 5 years was 61 %
(CI 52 %; 73 %), late relapses occurred in only two patients between 2 and 5 years of FU.
Twenty-five of the 34 relapses were detected at routine FU appointments. All 8 local recurrences were noted
clinically. Twenty-two patients had metastases confined to the lungs, either detected on CXR or CT. Thirty-two
percent of patients with lung metastases only were salvaged successfully.
Conclusions: Routine FU in high-grade osteosarcoma results in clinical detection of local relapse, and detection of
lung metastases by CXR at a time when metastatectomy is possible. The optimal time interval for FU appointments
is not known, however we recommend more frequent surveillance visits during the two years after treatment. We
hypothesize that routine CT scans are not required and propose CXR for detection of lung metastases.
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Background
High-grade osteosarcoma is the most common primary
bone tumour. It is a disease of childhood, adolescence
and young adulthood [1]. Osteosarcoma survival rates
for children and adolescents in Europe showed marked
improvement up to the 1980s [2] and many osteosar-
coma patients are cured by multi-agent chemotherapy
and surgery [3]. However, a significant number of pa-
tients who are rendered free of disease by initial chemo-
therapy and surgery develop disease relapse. The
opportunity to achieve a second complete remission by
surgical resection is essential for survival [4].
FU time intervals, duration and investigations vary
after treatment for high-grade extremity osteosarcoma
[5, 6]. FU is designed to detect either local recurrence or
metastatic disease at a time when early treatment is still
possible and might be effective [7]. One prospective ran-
domized trial on surveillance intensity in extremity sar-
coma (soft tissue and bone) was recently reported [8].
Nevertheless, the optimal frequency of FU and the best
radiologic method of lung surveillance continue to be
unknown. Radiation exposure is a concern especially in
young patients and should be balanced with the poten-
tial benefits of early detection of relapse [9, 10].
Methods
This is a retrospective analysis of 101 consecutive pa-
tients with high-grade extremity osteosarcoma who pre-
sented to a single institution for treatment and/or FU
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from 2003 to 2009. Routine FU consisted of clinical
examination, CXR and plain films of primary site 2-
monthly year 1, 3-monthly year 2 and 3, and 6-monthly
year 4 and 5. Confirmatory CT scans were performed in
all patients with suspicious findings. Routine CT scans
were performed at the end of treatment, when suspi-
cious finding had been observed previously and in a
patient with resected lung metastases. Patients were rou-
tinely seen and assessed by the treating oncologist or the
surgeon. Patient and tumour data were collected from
hospital records. Data collection was in accordance with
local ethical standards [11]. Survival rates were com-
puted using the method of Kaplan and Meier [12, 13].
As 50 % survival was not reached, 1, 2, and 5 year sur-
vival rates with 95 % confidence intervals are presented.
Event rates by site of relapse were examined using cu-
mulative incidence functions for survival data with com-
peting risks [14]. No hypothesis testing has been
performed. All analysis was performed in the R pro-
gramming language (version 3.2.2) [15].
Results
Median age at surgery was 18.7 years (range (4.7, 66.3)).
The primary tumour was located in the lower extremity
in 87 patients, and in the upper extremity in 14 patients.
Ninety-three patients had localized disease, 5 patients
had lung metastases at diagnosis, 2 patients a single
bone and 1 patient a lymph node metastasis. All patients
underwent surgery, 100 patients received chemotherapy,
92 pre- and postoperatively. Standard chemotherapy
consisted of high-dose methotrexate, doxorubicin and
cisplatin (MAP) [16]. Eight patients had radiotherapy. With
a median FU time of 30.7 months (range (2.2 months,
101.6 months)), 34 patients relapsed.
Five of the 8 patients with initial metastases (60 %),
and 29 patients with initially localised disease relapsed
(31 %). Of 34 patients with a relapse, 15 died (44 %).
Overall survival (OS) estimates for all patients at 1, 2,
and 5 years are 98, 94 and 73 %, respectively (Fig. 1).
Survival from time of relapse estimates at 1, 2, and
5 years are 88, 60 and 29 %, respectively (Fig. 2).
Twenty-five of the 34 relapses were detected at routine
FU appointments. All 8 local recurrences were noted
clinically, seven by the patients and one by the physician.
Signs or symptoms of local recurrence were masses or
swelling in 7 patients and pain in 1 patient, respectively.
Half of the local relapses were detected or reported at
routine FU, the other half outside scheduled appoint-
ments. The four patients with local relapse only were
treated with curative intent and three patients were sal-
vaged. However, three of the four patients with local re-
lapse and synchronous metastases died, one patient was
alive but not cured.
Twenty-two patients had metastases confined to the
lungs (Table 1). Three patients were symptomatic at re-
lapse with a pleural effusion, cough, and a pulmonary
embolism. In 10 patients routine CXR revealed pulmon-
ary metastases. In 9 patients lung metastases were de-
tected on planned CT: 4 on end of treatment scans, 3
with suspicious findings during or at end of treatment, 1
had lung metastases resected and was followed by CT, in
one patient the indication for a CT scan is unclear.
Nine of the 10 patients with CXR-detected lung me-
tastases were treated with curative intent by surgery only
(n = 4) or surgery and chemotherapy (n = 5) and 5
remain relapse-free. Among the 9 patients with CT
detected lung metastases 6 were treated with curative
intent and 2 remain relapse-free. In summary, 32 % of
patients with lung metastases only were salvaged
successfully. The higher rate of salvaged patients after
CXR-detected compared to CT-detected lung metastases
is probably attributable to the fact that the baseline risk
of relapse was higher in the patient group followed with
chest CT scans.
Most relapses occurred within the first two years after
end-of treatment and only two patients experienced a
relapse between years 2 to 5. Relapse-free survival esti-
mates at 1, 2, and 5 years are 83, 64 and 61 %, respect-
ively (Fig. 3).
In 101 patients, there were a total of 1’004 appoint-
ments without detection of relapse, corresponding with
costs of Great Britain Pound (GBP) 151’604 (outpatient
appointment (OPA) at University College London Hos-
pitals (UCH) + CXR + plain films of primary site) to GBP
287’144 (OPA at UCH + CT + plain films of primary
site). Median number of visits without relapse detected
was 8 (0–21), with costs of either GBP 1’210 (0 – 3’170)
or 2’290 (0 – 6’010). It is notable that none of the re-
lapses were detected after 26 months, even after a poten-
tial FU to 91 months.
Discussion
In this small retrospective analysis of 101 patients with
high-grade extremity osteosarcoma the median time to
relapse and the sites of relapse are similar to larger series
[3]. It confirms that the lungs are the main site of metas-
tases from osteosarcoma [17]. Nineteen of the 34
Table 1 Sites of relapse
Site n % of relapses
Local 4 12
Local and lung 3 9
Local and bone 1 3
Lung 22 65
Lung and bone 3 9
Bone 1 3
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Fig. 2 Overall survival after relapse
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patients (56 %) who experienced relapse were still alive
in our analysis after a median FU time of 30.7 months
(range (2.2 months, 101.6 months)); however FU was
much shorter compared to a previously reported series
of 110 relapsed osteosarcoma patients and a survival rate
of 16.4 % [4] after a median FU of 13.7 years (range
(4.6 years, 33.5 years)). In another retrospective analysis
the projected 5-year post relapse survival (PRS) rate was
28 %. Patients who had complete surgery of recurrence
had a 5-year PRS of 39 %, whereas for those who did not
have complete surgery, PRS was 0 % at 3 years [18]. The
importance of complete resection was also demonstrated
in two other retrospective reviews [19, 20]. Combination
chemotherapy may contribute to a modest improvement
in outcome for relapsed patients [3].
One limitation of this retrospective analysis is that we
cannot present data on histological response to preopera-
tive chemotherapy, which is an independent prognostic
parameter for relapse and survival [21]. In European and
American Osteosarcoma Study Group (EURAMOS)-1
50 % of osteosarcoma patients obtained a good response
to preoperative MAP chemotherapy, and 50 % had a poor
response [22]. After a median FU of 44 months 174 events
were reported in 716 patients with good histological re-
sponse [23], whereas 300 events were reported in 618 pa-
tients with a poor histological response after a median FU
of 54 months, respectively [24]. Due to the differences in
frequency of events, FU might ideally be adjusted to the
risk of relapse according to histological response.
We do not report on results of blood tests, which are
routinely performed during FU. We think blood tests
are unhelpful in detecting relapses. However, blood tests
might be useful to detect late organ toxicity following
intensive chemotherapy.
The only randomised trial of FU strategies in sarcoma
patients [8] compared chest imaging modalities (CXR
and CT scans) and frequency of FU (3-monthly and 6-
monthly visits) in 359 bone and 151 soft tissue extremity
sarcomas. CXR was non-inferior as compared with CT
scans (3-year OS 67 and 66 %, respectively; disease-free
survival 54 and 49 %, respectively). However the trial
could not conclusively demonstrate non-inferiority for
less frequent FU visits.
Most relapses in our series occurred within the first
two years after end-of treatment and when patients are
seen every two to three months, we therefore doubt that
more frequent visits and scans would have altered the
course of disease. However, we cannot exclude this nor
that in the two patients, who experienced a relapse be-
tween years 2 to 5, earlier detection of relapse would
have made treatment easier and more successful.
The question remains whether early relapse is a sign
of more aggressive disease and early detection can sub-
stantially change the course of the disease and outcome.
0.00
0.25
0.50
0.75
1.00
0 2 4 6
Time (years)
C
um
ul
at
iv
e 
In
ci
de
nc
e
local relapses
lung relapses
other relapses
Fig. 3 Cumulative incidence of relapse
Rothermundt et al. BMC Cancer  (2016) 16:301 Page 4 of 6
We previously reported data from a retrospective ana-
lysis of patients with extremity soft tissue sarcoma and
showed that routine CXR in FU can detect lung metas-
tases suitable for surgical resection. Local relapse of soft
tissue sarcoma is almost always detected by patients or
physicians, and routine scanning of the primary site is of
doubtful benefit [25]. In line with this data, we now
report a clinical detection rate of 100 % (8/8) for local
relapse in high-grade extremity osteosarcoma. X-rays of
the primary tumour site during surveillance of osteosar-
coma may be useful to inform on reconstructive results
and prosthesis function [26, 27], but are of little rele-
vance for detection of local relapse.
CXR detected pulmonary metastases in 10/22 patients,
9 patients underwent complete resection of lung metas-
tases, 5 of whom were relapse-free at last FU (2 after
surgery and 3 after surgery and chemotherapy). Patients
with CT detected pulmonary metastases were either
assessed at end of treatment (n = 4), due to suspicious
findings during or at end of treatment (n = 3), or after
lung metastases resection (n = 1). In one patient the rea-
son for a CT scan remains unclear. Among patients with
CT detected pulmonary metastases 2 remain relapse-
free at last FU. We postulate that CXR is sufficient for
routine scanning of the lungs, however we would advo-
cate CT scans in patients with suspicious findings on
CXR or previous abnormalities, which require following.
Conclusion
Routine FU with clinical examination by patient and
physician supplemented by CXR in high-grade extremity
osteosarcoma results in clinical detection of local re-
lapse, and detection of lung metastases at a time when
metastatectomy is possible. The optimal time interval
for FU appointments is not known. The higher relapse-
rate during the first two years of FU suggest more
frequent examination, however this has not been shown
to have impact on outcome. We hypothesize that 2- or 3-
monthly FU during the first 2 years after curative treat-
ment for high-grade extremity osteosarcoma with CXR is
feasible and may be sufficient in patients who had no pre-
vious abnormalities and remain asymptomatic.
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